Erwin R Boghaert Selected Research

hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide

7/2004

Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erwin R Boghaert Research Topics

Disease

22	Neoplasms (Cancer) 04/2021 - 01/2002
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 03/2004
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 03/2004
4	Glioblastoma (Glioblastoma Multiforme) 04/2021 - 01/2016
3	Carcinoma (Carcinomatosis) 11/2020 - 01/2002
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2015 - 02/2013
2	Multiple Myeloma 01/2016 - 10/2015
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2015 - 01/2006
1	Malignant Mesothelioma 10/2020
1	Hypoxia (Hypoxemia) 09/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2017
1	Lymphadenopathy 10/2015
1	Neutropenia 03/2015
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2014
1	Thrombocytopenia (Thrombopenia) 10/2014
1	Lymphoma (Lymphomas) 02/2013
1	Lung Neoplasms (Lung Cancer) 06/2011
1	Paralysis (Palsy) 12/2004

Drug/Important Bio-Agent (IBA)

11	Immunoconjugates (Immunoconjugate)IBA 04/2021 - 03/2004
7	CalicheamicinsIBA 07/2007 - 03/2004
5	venetoclaxIBA 01/2022 - 02/2013
5	Pharmaceutical PreparationsIBA 04/2021 - 07/2004
4	AntigensIBA 04/2021 - 07/2004
4	navitoclaxIBA 01/2016 - 02/2013
4	Inotuzumab OzogamicinIBA 01/2006 - 03/2004
3	depatuxizumab mafodotinIBA 04/2021 - 01/2018
2	Temozolomide (Temodar)FDA LinkGeneric 04/2021 - 01/2016
2	epidermal growth factor receptor VIIIIBA 04/2021 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2004
2	depatuxizumabIBA 01/2018 - 01/2016
2	EpitopesIBA 01/2018 - 01/2016
2	Cytotoxins (Cytolysins)IBA 02/2017 - 07/2007
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2013
2	Rituximab (Mabthera)FDA Link 07/2007 - 01/2006
2	Gemtuzumab (Mylotarg)FDA Link 03/2006 - 03/2004
2	HydrazinesIBA 07/2004 - 03/2004
2	Anti-Bacterial Agents (Antibiotics)IBA 07/2004 - 03/2004
1	Azacitidine (5 Azacytidine)FDA Link 01/2022
1	pevonedistatIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 04/2021
1	Biomarkers (Surrogate Marker)IBA 04/2021
1	A-1331852IBA 10/2020
1	auristatinIBA 10/2020
1	monomethylauristatin FIBA 01/2018
1	monomethyl auristatin EIBA 01/2018
1	InterleukinsIBA 09/2017
1	telisotuzumab vedotinIBA 02/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	Bortezomib (Velcade)FDA Link 01/2016
1	ABT-414IBA 01/2016
1	Docetaxel (Taxotere)FDA Link 03/2015
1	A-1155463IBA 10/2014
1	AcidsIBA 07/2007
1	Immunoglobulins (Immunoglobulin)IBA 03/2006
1	Lewis Y antigenIBA 07/2004
1	hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazideIBA 07/2004
1	Ephrin-A1 (Ephrin A1)IBA 01/2002

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 11/2020 - 03/2004
6	Therapeutics 01/2020 - 01/2005
1	Aftercare (After-Treatment) 04/2021
1	Injections 12/2004